Effect of Liraglutide on Pulsatile Insulin Secretion in Subjects With Type 2 Diabetes

Effect of NNC90-1170 on Pulsatile Insulin Secretion in Type 2 Diabetic Patients. A Double-blind, Placebo-controlled, Randomised, Single-dose, Cross-over Trial

This trial is conducted in Europe. The aim of this trial is to assess the effect of NNC 90-1170 (liraglutide) on pulsatile insulin secretion and insulin secretion after a standard meal in subjects with type 2 diabetes.

Inclusion Criteria:

• Diagnosed with type 2 diabetes, either newly diagnosed with at least two months of diet treatment, or in current OHA (oral hypoglycaemic agent) treatment with stable dose for at least six months
• BMI (Body Mass Index) between 24 and 35 kg/m^2 (both inclusive)
• Fasting plasma glucose between 6 and 15 mmol/l (both inclusive)
• Anti-GAD (glutamic acid decarboxylase) negative

Exclusion Criteria:

• Known or suspected allergy to trial product or related products
• Receipt of any investigational drug within three months prior to this trial
• Recurrent severe hypoglycaemia as judged by the investigator
• Cardiac disease or any clinically significant abnormal ECG (electrocardiogram)
• Use of any drug (except oral hypoglycaemic agents (OHAs)) which in the investigator's opinion could interfere
• with the blood glucose level (i.e., insulin, systemic corticosteroids, thiazides)
• Liver or renal disease